ABOS
Acumen Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$171.18M
P/E Ratio
—
EPS
$-1.85
Beta
0.35
52W High
$3.60
52W Low
$1.05
50-Day MA
$2.49
200-Day MA
$2.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
Fundamentals
| Revenue (TTM) | 329,000 |
| Gross Profit (TTM) | $-104.93M |
| EBITDA | $-114.56M |
| Operating Margin | 0.00% |
| Return on Equity | -93.20% |
| Return on Assets | -42.40% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $1.21 |
| Price-to-Book | 1.96 |
| Price-to-Sales (TTM) | 538.78 |
| EV/Revenue | 24.48 |
| EV/EBITDA | -0.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.23M |
| Float | $36.94M |
| % Insiders | 6.83% |
| % Institutions | 64.14% |
Historical Volatility
HV 10-Day
59.63%
HV 20-Day
64.93%
HV 30-Day
58.94%
HV 60-Day
66.29%
HV Rank
7.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.40 target)
6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026